Lumatix Biotech is developing a light-controlled affinity matrix for an effective and rapid isolation of antibodies.
Our new chromatography technology is intended to significantly advance antibody manufacturing, particular with regard to product quality as well as economic aspects. To achieve these ambitious goals and become a superior alternative to Protein A chromatography, we combine several proprietary technologies. The key innovation here is an affinity matrix with a light-controlled binding mode. By this means, the operator can easily capture antibodies in any user-defined buffer, making acidic elution obsolete.
Have a look at our website for further information and follow us on LinkedIn for fresh updates on our journey. There is a lot to come!
Imprint: https://www.lumatix.bio/imprint-data-protection/
Company Details
- Employees
- 1
- Founded
- 2021
- Address
- Lichtenbergstraße 8, Garching Bei München,germany
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.lumatix.bio
- HQ
- Garching bei München
Lumatix Biotech Questions
Lumatix Biotech's website is https://www.lumatix.bio
Lumatix Biotech's LinkedIn profile is https://de.linkedin.com/company/lumatix-biotech
Lumatix Biotech has
1 employees.
View email and phone details for 1
employees at Lumatix Biotech.
Lumatix Biotech's industry is
Biotechnology Research
Lumatix Biotech's top competitors are
Mxt Biotech,
Optieum Biotechnologies Inc.,
Hera Biotech,
Sweethoven Biotech,
Hydregen,
Rage Biotech,
Glyphic Biotechnologies,
Sumatrix Biotech,
Atanis Biotech Ag,
Hhv Biotech.
Lumatix Biotech's categories are Biotechnology Research
Lumatix Biotech's founding year is 2021
